Revisiones sistemáticas que incluyen este estudio

loading
7 articles (7 Referencias) loading Revertir Estudificar

Revisión sistemática

No clasificado

The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.

Revista European journal of clinical pharmacology
Año 2023
Enlaces Pubmed DOI

Este artículo incluye 10 Estudios primarios 10 Estudios primarios (10 referencias)

Cargando información sobre las referencias
PURPOSE: Previous studies have shown that tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can impair cognitive abilities. There is also some evidence that cannabidiol (CBD), the most abundant non-intoxicating constituent of cannabis, can attenuate these effects. The purpose of this study was to investigate the effects of THC, CBD oromucosal spray (with equal parts THC and CBD) on cognition compared with control conditions in human studies. METHODS: A systematic literature search was performed on four major bibliographic databases. Studies were included in the present review if they evaluated the cognitive effects of THC, CBD oromucosal spray compared with a control condition. RESULTS: Ten studies were identified (7 on patients with multiple sclerosis, 1 on those with Huntington, and 2 on healthy volunteers) with 510 participants in total. There was considerable heterogeneity among the studies in terms of dose and duration of administration. All studies have used an equal or nearly equal dose of THC and CBD. CONCLUSIONS: Although the results across studies were somewhat inconsistent, most evidence revealed that there is no significant difference between THC, CBD oromucosal spray and control treatments in terms of cognitive outcomes. However, more trials are needed with longer follow-up periods, and dose considerations, particularly comparing lower and higher doses of the spray.

Revisión sistemática

No clasificado

The "Next Day" Effects of Cannabis Use: A Systematic Review.

Revista Cannabis and cannabinoid research
Año 2023
Enlaces Pubmed DOI PubMed Central

Este artículo incluye 20 Estudios primarios 20 Estudios primarios (20 referencias)

Cargando información sobre las referencias
ABSTRACT: Background: Δ9-Tetrahydrocannabinol (THC), the main intoxicating component of cannabis, can cause cognitive and psychomotor impairment. Whether this impairment is still present many hours or even days after THC use requires clarification. Possible "next day" effects are of major significance in safety-sensitive workplaces. We therefore conducted a systematic review of studies investigating the "next day" effects of THC. METHODS: Studies that measured performance on safety-sensitive tasks (e.g., driving, flying) and/or neuropsychological tests >8 h after THC (or cannabis) use using interventional designs were identified by searching two online databases from inception until March 28, 2022. Risk of bias (RoB) was evaluated using the relevant Cochrane tools. Results were described in terms of whether THC had a significant effect on performance relative to the primary comparator (i.e., placebo or baseline, as appropriate). RESULTS: Twenty studies (n=458) involving 345 performance tests were reviewed. Most studies administered a single dose of THC (median [interquartile range]: 16 [11-26] mg) and assessed performance between >12 and 24 h post-treatment. N=209/345 tests conducted across 16 published studies showed no "next day" effects of THC. Nine of these 16 studies used randomized, double-blind, placebo-controlled designs. Half (N=8) had "some" RoB, and half (N=8) had a "high" RoB. Notably, N=88 of these 209 tests failed to demonstrate "acute" (i.e., <8 h post-treatment) THC-induced impairment. N=12/345 tests conducted across five published studies indicated negative (i.e., impairing) "next day" effects of THC. None of these five studies used randomized, double-blind, placebo-controlled designs and all were published >18 years ago (four, >30 years ago). Three had "some" RoB, and two had a "high" RoB. A further N=121/345 tests indicated "unclear" "next day" effects of THC with insufficient information provided to assess outcomes. The remaining N=3/345 tests indicated positive (i.e., enhancing) "next day" effects of THC. CONCLUSIONS: Some lower quality studies have reported "next day" effects of THC on cognitive function and safety-sensitive tasks. However, most studies, including some of higher quality, have found no such effect. Overall, it appears that there is limited scientific evidence to support the assertion that cannabis use impairs "next day" performance. Further studies involving improved methodologies are required to better address this issue.

Revisión sistemática

No clasificado

Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies.

Revista Progress in neuro-psychopharmacology & biological psychiatry
Año 2021
Enlaces Pubmed DOI

Este artículo está incluido en 1 Síntesis amplia 52 Síntesis amplias (1 referencia)

Este artículo incluye 52 Estudios primarios 52 Estudios primarios (52 referencias)

Cargando información sobre las referencias
BACKGROUND: Impairment in cognition is frequently associated with acute cannabis consumption. However, some questions remain unanswered as to which deficits are most prominent and which demographic groups are most vulnerable. METHODS: A literature search yielded 40 experimental studies of acute administration of partial CB1 receptor agonists (i.e. cannabis, THC, and nabilone) that assessed cognitive dysfunction in 1403 healthy volunteers. Effect size estimates were calculated using the Comprehensive Meta-Analysis for the following six cognitive domains: attention, executive functions, impulsivity, speed of processing, verbal learning/memory, and working memory. RESULTS: There were small-to-moderate impairments across all cognitive domains. Deficits in verbal learning/memory and working memory were more prominent, whereas attention and impulsivity were the least affected. Meta-regression analysis revealed that the greater the male ratio is in a sample, the greater the negative effect of cannabinoids on speed of processing and impulsivity. Analysis of route of administration showed that the deficits in speed of processing were smaller in the oral, relative to smoking, vaping, and intravenous administration studies. A publication bias was observed. DISCUSSION: Verbal learning/memory and working memory are most prominently affected by acute administration of partial CB1 receptor agonists. The results are consistent with the residual cognitive effects that have been documented among chronic cannabis users.

Revisión sistemática

No clasificado

Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review.

Revista Neuroscience and biobehavioral reviews
Año 2021
Enlaces Pubmed DOI

Este artículo está incluido en 1 Síntesis amplia 80 Síntesis amplias (1 referencia)

Este artículo incluye 81 Estudios primarios 80 Estudios primarios (81 referencias)

Cargando información sobre las referencias
The increasing legal availability of cannabis has important implications for road safety. This systematic review characterised the acute effects of Δ9-THC on driving performance and driving-related cognitive skills, with a particular focus on the duration of Δ9-THC-induced impairment. Eighty publications and 1534 outcomes were reviewed. Several measures of driving performance and driving-related cognitive skills (e.g. lateral control, tracking, divided attention) demonstrated impairment in meta-analyses of "peak" Δ9-THC effects (p's<0.05). Multiple meta-regression analyses further found that regular cannabis use was associated with less impairment than 'other' (mostly occasional) cannabis use (p = 0.003) and that the magnitude of oral (n = 243 effect estimates [EE]) and inhaled (n = 481 EEs) Δ9-THC-induced impairment depended on various factors (dose, post-treatment time interval, the performance domain (skill) assessed) in other cannabis users (p's<0.05). The latter model predicted impairment would take ∼7 -hs to subside (Hedges' g=-0.25) after inhaling 20 mg of Δ9-THC; oral Δ9-THC-induced impairment may take longer to subside. These results suggest individuals should wait at least 7 -hs following inhaled cannabis use before performing safety-sensitive tasks.

Revisión sistemática

No clasificado

The use of cannabinoids for sleep: A critical review on clinical trials.

Revista Experimental and clinical psychopharmacology
Año 2019
Enlaces Pubmed DOI

Este artículo incluye 42 Estudios primarios 42 Estudios primarios (42 referencias)

Cargando información sobre las referencias
Cannabis and its pharmacologically active constituents, phytocannabinoids, have long been reported to have multiple medicinal benefits. One association often reported by users is sedation and subjective improvements in sleep. To further examine this association, we conducted a critical review of clinical studies examining the effects of cannabinoids on subjective and objective measures of sleep. PubMED, Web of Science, and Google Scholar were searched using terms and synonyms related to cannabinoids and sleep. Articles chosen included randomized controlled trials and open label studies. The Cochrane risk of bias tool was used to assess the quality of trials that compared cannabinoids with control interventions. The current literature focuses mostly on the use of tetrahydrocannabinol (THC) and/or cannabidiol (CBD) in the treatment of chronic health conditions such as multiple sclerosis, posttraumatic stress disorder (PTSD), and chronic pain. Sleep is often a secondary, rather than primary outcome in these studies. Many of the reviewed studies suggested that cannabinoids could improve sleep quality, decrease sleep disturbances, and decrease sleep onset latency. While many of the studies did show a positive effect on sleep, there are many limiting factors such as small sample sizes, examining sleep as a secondary outcome in the context of another illness, and relatively few studies using validated subjective or objective measurements. This review also identified several questions that should be addressed in future research. These questions include further elucidation of the dichotomy between the effects of THC and CBD, as well as identifying any long-term adverse effects of medicinal cannabinoid use. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Revisión sistemática

No clasificado

Los efectos de la administración de cannabinoides en el sueño: una revisión sistemática de los estudios en humanos.

automatic
Revista Sleep medicine reviews
Año 2014
Enlaces Pubmed DOI

Este artículo está incluido en 3 Síntesis amplias 38 Síntesis amplias (3 referencias)

Este artículo incluye 39 Estudios primarios 38 Estudios primarios (39 referencias)

Cargando información sobre las referencias
Este artículo revisa la literatura sobre los efectos de la administración de cannabinoides sobre el sueño en los seres humanos. Se realizó una búsqueda bibliográfica a través de un conjunto de cannabinoides y los términos relacionados con el sueño en ocho bases de datos electrónicas. Se incluyeron los estudios en humanos que participan la administración de cannabinoides y al menos una medida cuantitativa relacionada con el sueño. Los artículos de revisión, artículos de opinión, cartas o editoriales, estudios de casos (Final N <7), publicaron fueron excluidos resúmenes, carteles y documentos no están en inglés. Treinta y nueve publicaciones fueron incluidos en la revisión. Los resultados fueron mixtos y mostraron diferentes efectos de la administración de cannabinoides sobre varios aspectos del sueño. Aspectos metodológicos en la mayoría de los estudios realizados hasta la fecha, sin embargo, no permiten obtener conclusiones definitivas.

Revisión sistemática

No clasificado

El cannabidiol en los seres humanos: la búsqueda de dianas terapéuticas.

automatic
Autores Zhornitsky S , Potvin S
Revista Pharmaceuticals (Basel, Switzerland)
Año 2012
Enlaces Pubmed DOI PubMed Central

Este artículo está incluido en 10 Síntesis amplias 34 Síntesis amplias (10 referencias)

Este artículo incluye 40 Estudios primarios 34 Estudios primarios (40 referencias)

Cargando información sobre las referencias
El cannabidiol (CBD), un componente importante fitocannabinoide de cannabis, está atrayendo cada vez más atención en medicina por su ansiolíticos, antipsicóticos, antieméticos y propiedades anti-inflamatorias. Sin embargo, hasta este momento, una revisión exhaustiva de la literatura de los efectos del CDB en los seres humanos es insuficiente. El objetivo de la presente revisión sistemática es examinar los estudios aleatorizados y cruzados que administraron CDB con los controles sanos y pacientes clínicos. Una búsqueda sistemática se realizó en las bases de datos electrónicas PubMed y EMBASE usando la palabra clave "cannabidiol". Se incluyeron en monoterapia y combinación de estudios (por ejemplo, el CDB + Δ9-THC). Un total de 34 estudios se identificaron: 16 de ellos eran estudios experimentales, realizado en individuos sanos, y 18 se realizaron en poblaciones clínicas, incluyendo la esclerosis múltiple (seis estudios), la esquizofrenia y la manía bipolar (cuatro estudios), el trastorno de ansiedad social (dos estudios), neuropático y dolor por cáncer (dos estudios), anorexia cáncer (un estudio), la enfermedad de Huntington (un estudio), el insomnio (un estudio), y la epilepsia (un estudio). Los estudios experimentales indican que se requiere una alta dosis de inhalación / intravenosa CDB para inhibir los efectos de una dosis más baja de Δ9-THC. Por otra parte, algunos estudios experimentales y clínicos sugieren que la vía oral / vía bucal CDB puede prolongar y / o intensificar Δ9-THC-inducida efectos, mientras que otros sugieren que puede inhibir los efectos inducidos por el Δ9-THC. Por último, los ensayos clínicos preliminares sugieren que altas dosis oral de CDB (150-600 mg / d) puede ejercer un efecto terapéutico para el trastorno de ansiedad social, el insomnio y la epilepsia, sino que también puede causar sedación mental. Se discuten farmacocinéticos y farmacodinámicos posibles explicaciones para estos resultados.